newsfilter
← Latest News
GlobeNewswire·

Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request

Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system SARASOTA, FLA., June 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the